Acura Pharmaceuticals Secures Insider Loans Amid Liquidity Strain

An update from Acura Pharmaceuticals ( (ACUR) ) is now available.

Acura Pharmaceuticals disclosed that between March 30 and May 5, 2026 it received four additional $100,000 loans from major shareholder Abuse Deterrent Pharma, LLC, bringing the principal on its secured promissory note to $10.29 million with about $1.09 million of accrued interest at a 5.25% rate, rising to 7.5% on overdue amounts. The funding is being used to cover day‑to‑day operations, but management warned that without further financing by the end of May 2026 it may be forced to scale back or shut down operations and potentially seek bankruptcy protection, jeopardizing shareholder value while highlighting the company’s heavy dependence on AD Pharma, which controls roughly 65% of its stock plus additional warrants.

As of April 30, 2026 AD Pharma owned about 65% of Acura’s outstanding common stock, excluding a warrant for 10 million additional shares, while an affiliated investor, Mr. Schutte, directly held a further 13%. This growing reliance on insider-controlled debt financing underlines Acura’s constrained liquidity position and heightens governance and concentration risks for minority shareholders as the June 30, 2026 note and regulatory milestones approach.

More about Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a specialty drug developer focused on products that incorporate abuse-deterrent technologies, including its LIMITx and Impede platforms aimed at reducing misuse of opioid and other medications. The company operates in the pharmaceutical industry, targeting regulated prescription and potential over-the-counter markets in the U.S. through internally developed candidates and licensing partnerships.

Average Trading Volume: 120

Technical Sentiment Signal: Sell

Current Market Cap: $33K

Learn more about ACUR stock on TipRanks’ Stock Analysis page.